A Study to Evaluate the Efficacy and Safety of IN-115314 Ointment in Mild to Moderate Atopic Dermatitis Adult Patients

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

162

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Mild to Moderate Atopic Dermatitis

Interventions

DRUG

IN-115314 Ointment 1%

Twice daily(BID), for 56 day

DRUG

IN-115314 Ointment 3%

Twice daily(BID), for 56 day

DRUG

IN-115314 Ointment placebo

Twice daily(BID), IN-115314 Ointment Placebo for 28 days+ IN-115314 Ointment 3% for 28 days